NCT06934915View on ClinicalTrials.gov

Prednisone in Adults With an Immune-Mediated Subtype of Autism Spectrum Disorder

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

June 30, 2028

Study Completion Date

January 31, 2029

Conditions
Autism Spectrum Disorder
Interventions
DRUG

Prednisone

Starting dose: 5 mg daily. Maximum dose: 60 mg daily. Dosage forms: 5 mg, 10 mg, and 20 mg capsules.

DRUG

Placebo

Capsules identical in size and appearance to those containing prednisone. Placebo capsules contain inactive ingredients.

Trial Locations (1)

02421

Massachusetts General Hospital, Lexington

All Listed Sponsors
lead

Christopher John McDougle, M.D.

OTHER

NCT06934915 - Prednisone in Adults With an Immune-Mediated Subtype of Autism Spectrum Disorder | Biotech Hunter | Biotech Hunter